Manage episode 275276297 series 2391742
We interrupt our normal FOAMcast episodes to bring you updates from COVID-19. *Our understanding of COVID-19 is rapidly developing and this may be out of date in days/weeks. So, check back for updates/fact check what you hear*
Monoclonal antibodies have received significant attention over the past month and we previously podcasted on antibodies that target SARS-CoV-2. In this episode, we review several recent studies on a different "mab", tocilizumab, which targets inflammation mediated by interleukin-6 that is overly ramped up.
Stone et al ( RCT)
Salvarani et al. (RCT)
Show notes (references/graphics): FOAMcast.org
Thanks for listening, Lauren Westafer and Jeremy Faust